Skip to main content
Top

14-03-2024 | Tuberculosis | Images in clinical gastroenterology

Esophageal tuberculosis

Authors: Qian Hu, Shi-Hua Zheng, Wei Liu

Published in: Indian Journal of Gastroenterology

Login to get access

Excerpt

A 57-year-old man presented with a one-week history of odynophagia, diarrhea, and fever. Physical examination was unremarkable. Laboratory tests showed red blood cell count of 4.17 × 1012/L (normal range, 4.3–5.8 × 1012/L), leukocyte count of 9.94 × 109/L (normal range, 3.5–9.5 × 109/L), platelet count of 381 × 109/L (normal range, 125–350 × 109/L), hemoglobin of 105 g/L (normal range, 130–175 g/L), erythrocyte sedimentation rate of 98 mm/h (normal range, 0–20 mm/h), C-reaction protein of 52 mg/L (normal range, 0–5 mg/L), total serum protein of 61 g/L (normal range, 65–85 g/L) and serum albumin of 29 g/L (normal range, 40–55 g/L). Esophagogastroduodenoscopy showed deep longitudinal ulcers in the lower esophageal region at 32 to 40 cm from the incisor (Fig. 1A). Colonoscopy revealed ulcer lesions in the ileocecal valve and ascending colon. No enlarged mediastinal lymph nodes were found in adjacent areas by computed tomography (CT) scan. Esophageal and colonic biopsy specimens (H&E staining) showed chronic inflammation with lymphocytic infiltration and caseating granulomas (Fig. 1B). The histopathological features of the esophageal and colonic biopsies indicated the possibility of esophageal tuberculosis. Chest CT showed no signs of pulmonary tuberculosis. The purified protein derivative (PPD) skin test, T-SPOT.TB assay and polymerase chain reaction testing for M tuberculosis were positive. The human immunodeficiency virus (HIV) enzyme-linked immunosorbent assay (ELISA) test was negative. Immunosuppressant conditions were excluded in this patient. Finally, a diagnosis of primary esophageal and intestinal tuberculosis was made. Esophageal tuberculosis is extremely rare and symptoms are related to the extent of infection [13]. The patient received a standard oral antituberculous regimen. Repeat endoscopy examination showed that the esophageal and colonic ulcers healed after 12 months of antituberculosis treatment.
Literature
1.
go back to reference Han DG, Wang DC, Liu W. Primary esophageal tuberculosis. Clin Res Hepatol Gastroenterol. 2023;47:102242. Han DG, Wang DC, Liu W. Primary esophageal tuberculosis. Clin Res Hepatol Gastroenterol. 2023;47:102242.
2.
go back to reference Zhou MD, Han DG, Liu W. Esophagomediastinal fistula secondary to tuberculous mediastinal lymphadenopathy. Clin Res Hepatol Gastroenterol. 2023;47:102243. Zhou MD, Han DG, Liu W. Esophagomediastinal fistula secondary to tuberculous mediastinal lymphadenopathy. Clin Res Hepatol Gastroenterol. 2023;47:102243.
3.
go back to reference Birda CL, Antriksh K, Gupta P. Oesophageal tuberculosis: a systematic review focusing on clinical management. Dysphagia. 2022;37:973–87.CrossRefPubMed Birda CL, Antriksh K, Gupta P. Oesophageal tuberculosis: a systematic review focusing on clinical management. Dysphagia. 2022;37:973–87.CrossRefPubMed
Metadata
Title
Esophageal tuberculosis
Authors
Qian Hu
Shi-Hua Zheng
Wei Liu
Publication date
14-03-2024
Publisher
Springer India
Published in
Indian Journal of Gastroenterology
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-024-01533-1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.